Strong Sales Growth
Sales in the fourth quarter were $1.045 billion, an increase of 12% in both local currency and US dollars.
Regional Performance Highlights
Local currency sales grew 19% in Europe and 14% in Asia/Rest of World for the quarter. Full-year growth in Europe was 8%.
Laboratory Segment Success
For the quarter, Laboratory sales increased 18%, driven by strong demand in Europe and among pharma and biopharma customers.
Gross Margin Improvement
Gross margin increased to 61.2% in the quarter, a rise of 220 basis points, driven by higher volume, positive price realization, and productivity initiatives.
Adjusted EPS Growth
Adjusted EPS for the quarter was $12.41, marking a 32% increase over the prior year.
Positive Outlook for 2025
Full-year adjusted EPS for 2025 is expected to grow 3% to 5%, or 9% to 10% excluding the impact of shipping delays and unfavorable currency.